371 related articles for article (PubMed ID: 24875764)
1. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
[TBL] [Abstract][Full Text] [Related]
2. Construction of an aptamer modified liposomal system targeted to tumor endothelial cells.
Ara MN; Matsuda T; Hyodo M; Sakurai Y; Ohga N; Hida K; Harashima H
Biol Pharm Bull; 2014; 37(11):1742-9. PubMed ID: 25366480
[TBL] [Abstract][Full Text] [Related]
3. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
[TBL] [Abstract][Full Text] [Related]
4. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361
[TBL] [Abstract][Full Text] [Related]
5. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.
Kibria G; Hatakeyama H; Harashima H
Int J Pharm; 2011 Jun; 412(1-2):106-14. PubMed ID: 21414394
[TBL] [Abstract][Full Text] [Related]
6. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
Ishitsuka T; Akita H; Harashima H
J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
[TBL] [Abstract][Full Text] [Related]
7. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.
Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q
Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793
[TBL] [Abstract][Full Text] [Related]
8. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery.
Tang J; Fu H; Kuang Q; Zhang L; Zhang Q; Liu Y; Ran R; Gao H; Zhang Z; He Q
J Drug Target; 2014 May; 22(4):313-26. PubMed ID: 24404866
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.
Yang X; Zhao J; Duan S; Hou X; Li X; Hu Z; Tang Z; Mo F; Lu X
Theranostics; 2019; 9(14):4066-4083. PubMed ID: 31281532
[No Abstract] [Full Text] [Related]
10. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.
Kuai R; Yuan W; Qin Y; Chen H; Tang J; Yuan M; Zhang Z; He Q
Mol Pharm; 2010 Oct; 7(5):1816-26. PubMed ID: 20701288
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Nucleoporin358-Specific RNA Aptamer for Use as a Nucleus-Targeting Liposomal Delivery System.
Shrivastava G; Hyodo M; Yoshimura SH; Akita H; Harashima H
Nucleic Acid Ther; 2016 Oct; 26(5):286-298. PubMed ID: 27548508
[TBL] [Abstract][Full Text] [Related]
12. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
[TBL] [Abstract][Full Text] [Related]
13. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
14. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
15. Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro.
Mu C; Dave N; Hu J; Desai P; Pauletti G; Bai S; Hao J
J Microencapsul; 2013; 30(7):701-8. PubMed ID: 23517066
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration.
Kuai R; Yuan W; Li W; Qin Y; Tang J; Yuan M; Fu L; Ran R; Zhang Z; He Q
Mol Pharm; 2011 Dec; 8(6):2151-61. PubMed ID: 21981683
[TBL] [Abstract][Full Text] [Related]
17. A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence.
Akhter A; Hayashi Y; Sakurai Y; Ohga N; Hida K; Harashima H
Int J Pharm; 2013 Nov; 456(1):195-201. PubMed ID: 23933440
[TBL] [Abstract][Full Text] [Related]
18. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
19. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
20. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
